The Indira IVF Sabine acquisition is reportedly under discussion: India’s largest fertility services provider is said to be in advanced talks to buy a majority stake in Kerala-based Sabine Hospital and Research Centre in a deal that could be worth ₹1,200 crore to ₹1,300 crore. The reports describe a possible 70% to 75% stake. Nothing has been confirmed by either company, and the transaction is not a completed acquisition.
Key takeaways from the Indira IVF Sabine acquisition reports
- Reported value: ₹1,200 crore to ₹1,300 crore for a stake of about 70% to 75%.
- Sabine runs two facilities in Kerala with about 300 beds, and is reported to handle more than 6,000 IVF cycles a year.
- The reported seller is CX Partners, which is said to have invested in Sabine only last year.
- The next steps reported are valuation, due diligence and regulatory approvals.
- Neither company has confirmed the talks in the material we reviewed, and Sabine’s financials have not been disclosed.
What is reported about the Indira IVF Sabine acquisition
The story originates in a business-press report dated 28 October 2026 and has been repeated by other outlets. It says the discussions are at an advanced stage and that O3 Capital is facilitating them. We have not seen a statement from Indira IVF, Sabine or CX Partners, and the follow-up reports we read name no sources and quote no executives. Treat every figure as a report of talks and not as agreed terms. Indira IVF publishes company information at indiraivf.com.
The brief for this story described the transaction as a potential deal that is not completed, and that is how we present it. We have not confirmed the sale price, the stake or the timeline with the companies.
Who is Sabine Hospital and Research Centre
Sabine was founded in 2010 by Dr Sabine Sivadasan and, according to the reports, operates two facilities in Kerala with around 300 beds including specialised neonatal care capacity. It provides fertility, maternity and newborn-care services. The reports credit it with more than 6,000 IVF cycles a year, a figure we could not verify independently. The precise locations of the two sites within Kerala were not given. No revenue, profit or earnings figures have been published in the sources we read, so we cannot say what multiple the reported price implies.
Why Kerala matters in the Indira IVF Sabine acquisition
The reports say the deal would give Indira IVF an entry into Kerala and help it scale faster nationally ahead of its planned stock-market listing, which has been reported as aiming to raise about ₹3,500 crore. They also say a rival, Nova IVF Fertility, recently entered Kerala by acquiring Craft Fertility. Both points are attributed to the reports and are not confirmed by the companies. Kerala has a well-developed private hospital sector, and a chain that combines fertility with maternity and newborn care could keep patients in one network from conception to birth, which is the strategic logic usually cited for such deals.
Timeline of the Indira IVF Sabine acquisition
- 2010: Sabine is founded in Kerala.
- 2025: Indira IVF’s planned public listing is reported, with draft papers filed confidentially.
- 2025 to 2026: Indira IVF is reported to have acquired centres in Kolkata, Puducherry and Gujarat.
- Last year: CX Partners is reported to have invested in Sabine.
- 28 October 2026: reports emerge of advanced talks for a 70% to 75% stake.
Market context for the Indira IVF Sabine acquisition
Acumen Research and Consulting’s report In-Vitro Fertilization Market Size, Share, Analysis, Trends and Forecast 2024 to 2032 values the global in-vitro fertilisation market at USD 25.57 billion in 2023 and projects USD 44.28 billion by 2032, a compound annual growth rate of 6.4% from 2024 to 2032. It says Asia Pacific is expected to be the fastest-growing region at more than 7.2% a year, and that fertility clinics accounted for around 80% of the market in 2023. The page’s updated date predates its base year, so treat the figures as estimates. They are global and are not specific to India or Kerala. See more in our Healthcare Services coverage.
Regulation and the Indira IVF Sabine acquisition
Indian fertility providers operate under the Assisted Reproductive Technology (Regulation) Act, according to the reports. Any acquisition would also need the usual corporate and, depending on size, competition approvals. The Ministry of Health and Family Welfare publishes related material at mohfw.gov.in. We have not seen the approvals the companies expect to need.
General background: consolidation in Indian fertility care
Fertility treatment in India has been consolidating as chains buy independent clinics and hospitals to build national networks, and investors have shown interest in specialised healthcare chains. Chains gain scale in purchasing, branding and doctor recruitment, while founders and early investors gain an exit. Clinical quality, however, depends on individual centres, and acquisitions have to preserve it.
Our analysis of the Indira IVF Sabine acquisition
In our assessment, the Indira IVF Sabine acquisition would be a logical step if the reports are accurate: a national leader gets a foothold in a high-income state and a hospital platform that adds maternity and neonatal services to fertility. The uncertainty is large. The price is reported as a range, the seller would be exiting after roughly a year, and no financials are available, so we cannot judge value. We do not predict whether the deal will be signed.
What is not disclosed about the Indira IVF Sabine acquisition
- Official confirmation from the companies.
- Sabine’s revenue, profit and debt.
- The final price, stake and structure.
- Closing timeline and approvals needed.
Risks and caveats
This is a report of talks that may not result in a deal. Terms can change or the discussions can end. Figures come from press reports and are unverified. This article is news reporting and not investment advice.
What to watch next
- A formal announcement or stock-exchange disclosure from Indira IVF.
- The draft prospectus, whose filing is overseen by SEBI.
- Competitive moves by other fertility chains in Kerala.
- Disclosure of Sabine’s financial results.
FAQ
Has the Indira IVF Sabine acquisition been completed?
No. It is reported as under discussion and has not been confirmed.
How much is the deal reportedly worth?
₹1,200 crore to ₹1,300 crore for a 70% to 75% stake, according to reports.
What is Sabine Hospital known for?
Fertility, maternity and newborn-care services at two facilities in Kerala.
How we reported this: we relied on press reports of the talks, company websites, regulator sites and the Acumen Research and Consulting report cited above, and attributed every claim. Last updated 28 October 2026. This is news reporting and not advice.